title: Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4.
abstract: Aquaporin-4 (AQP4) plays a role in the generation of post-ischemic edema. Pharmacological modulation of AQP4 function may thus provide a novel therapeutic strategy for the treatment of stroke, tumor-associated edema, epilepsy, traumatic brain injury, and other disorders of the central nervous system (CNS) associated with altered brain water balance. Edaravone, a free radical scavenger, is used for the treatment of acute ischemic stroke (AIS) in Japan. In this study, edaravone significantly reduced the infarct area and improved the neurological deficit scores at 24h after reperfusion in a rat transient focal ischemia model. Furthermore, edaravone markedly reduced AQP4 immunoreactivity and protein levels in the cerebral infarct area. In light of observations that edaravone specifically inhibited AQP4 in a rat transient focal ischemia model, we propose that edaravone might reduce cerebral edema through the inhibition of AQP4 expression following cerebral infarction.
authors.affiliation: Division of Laboratory and Vascular Medicine, Field of Cardiovascular and Respiratory Disorders, Department of Advanced Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Salunya
authors.initials: S
authors.lastname: Tancharoen
authors.forename: Fumiyo
authors.initials: F
authors.lastname: Matsuda
authors.forename: Kamal Krishna
authors.initials: KK
authors.lastname: Biswas
authors.forename: Takashi
authors.initials: T
authors.lastname: Ito
authors.forename: Yoko
authors.initials: Y
authors.lastname: Morimoto
authors.forename: Yoko
authors.initials: Y
authors.lastname: Oyama
authors.forename: Kazunori
authors.initials: K
authors.lastname: Takenouchi
authors.forename: Naoki
authors.initials: N
authors.lastname: Miura
authors.forename: Noboru
authors.initials: N
authors.lastname: Arimura
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nawa
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Meng
authors.forename: Binita
authors.initials: B
authors.lastname: Shrestha
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Arimura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Iwata
authors.forename: Kentaro
authors.initials: K
authors.lastname: Mera
authors.forename: Hisayo
authors.initials: H
authors.lastname: Sameshima
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Ohno
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Maenosono
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tajima
authors.forename: Hisaaki
authors.initials: H
authors.lastname: Uchikado
authors.forename: Terukazu
authors.initials: T
authors.lastname: Kuramoto
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakayama
authors.forename: Minoru
authors.initials: M
authors.lastname: Shigemori
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Teruto
authors.initials: T
authors.lastname: Hashiguchi
authors.forename: Ikuro
authors.initials: I
authors.lastname: Maruyama
authors.forename: Ko-Ichi
authors.initials: K
authors.lastname: Kawahara
mesh_terms: D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051401:Aquaporin 4 / Q000037:antagonists & inhibitors*; D001929:Brain Edema / Q000188:drug therapy* / Q000209:etiology; D002545:Brain Ischemia / Q000150:complications*; D004195:Disease Models, Animal; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D008297:Male; D051381:Rats
chemical_list: D051401:Aquaporin 4; D016166:Free Radical Scavengers; D000077553:Edaravone; D000983:Antipyrine